BioSpace News Archive

Virios Therapeutics, Inc. (the “Company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $30 million, before deducting underwriting discounts, commissions and o

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 million doses of NVX-CoV2373, Novavax’ candidate vaccine against COVID-19. Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein

Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs)

Cigna’s International Markets business published the fourth edition of its COVID-19 Global Impact Study, which reveals that people are increasingly worried about the long-term impact of the COVID-19 pandemic.

Matrix Medical Network ® (Matrix) today announced the completion of the integration of Biocerna, a state-of-the-art CLIA-certified and CAP-accredited laboratory dedicated to delivering clinical

A scientist since childhood, Jain will now lead a lab at Gladstone to study the balance of oxygen levels in the human body

PrEP Biopharm Limited, a private drug company developing treatments for respiratory infectious diseases, announced that it has successfully completed a 12-week toxicology study in dogs. There were no mortalities and no test item-related changes in clinical signs, body weights, food consumption, or other systemic nor macroscopic adverse

Health Canada is warning Canadians about the risks of buying COVID-19 vaccines sold on the internet or from unauthorized sources as they are counterfeit and may pose serious health risks.

In vivo data after single-dose IV administration demonstrate engagement with DMPK mRNA and broad rescue of mis-splicing across key transcripts Findings provide support for hypothesized mechanism of action of anti-gene, which is designed to not degrade the DMPK transcript Data further validate the potential of the PATrOL™ platform to develop highly targeted therapies that increase, decrease or change causal protein function

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Company”) today reported its audited financial results for the fiscal year ended October 31, 2020. Unless otherwise noted, all figures are in Canadian currency. “By all measures, Avivagen achieved considerable regulatory, customer, corporate and financial success in 2020,” said Kym Anthony, President and Chief Executive Officer, Avivagen Inc. “We’ve secured r